Form 4: Labcorp EVP Converts RSUs, Sells Shares for Tax

Labcorp's EVP of Diagnostics, Bryan T. Vaughn, converted Restricted Stock Units into common stock and sold a portion to cover tax obligations.

Summary

• Bryan T. Vaughn, EVP, Diagnostics at Labcorp Holdings Inc. (LH), reported transactions involving the company's common stock and Restricted Stock Units (RSUs).
• On February 11, 2026, Vaughn acquired 323 shares of common stock through the conversion of Restricted Stock Units.
• Concurrently, 93 shares of common stock were disposed of at a price of $289.89 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Vaughn directly beneficially owns 5,612.5702 shares of common stock.
• Vaughn also holds 4,031 Restricted Stock Units, which represent the contingent right to receive one share of common stock per unit.
• The vested RSUs were part of a grant that vests in three equal annual installments, commencing on February 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports a routine insider transaction involving equity compensation and tax withholding, which is a common occurrence and does not indicate a significant change in company fundamentals or outlook.

Positives

• The conversion of Restricted Stock Units into common stock indicates a vesting event, allowing the executive to realize value from their equity compensation.
• The executive continues to hold a significant number of common shares (5,612.5702) and additional RSUs (4,031), aligning their interests with shareholders.

Negatives

• A portion of the vested shares (93 shares) was sold to cover tax withholding obligations, resulting in a reduction of direct common stock ownership.

Future Outlook

The remaining 4,031 Restricted Stock Units held by Bryan T. Vaughn are scheduled to vest in equal annual installments, continuing from the initial vesting date of February 11, 2026.

Industry Context

StockSavvy.ai notes that routine insider transactions, such as RSU conversions and subsequent tax-related sales, are common across all industries, particularly in mature companies like Labcorp. These transactions typically reflect pre-scheduled equity compensation plans rather than new strategic shifts or market outlooks.

Comparison to Industry Standards

• The RSU vesting and tax-related sale are standard practices for executive compensation in publicly traded companies, aligning with typical equity incentive structures seen in healthcare and diagnostic services firms such as Quest Diagnostics (DGX) or Eurofins Scientific (ERF.PA).

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-scheduled insider transaction related to executive compensation, not a change in company strategy or performance.
• Employees: No direct impact indicated by this filing.

Next Steps

• Future vesting of the remaining 4,031 Restricted Stock Units in equal annual installments, commencing February 11, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are common and typically pre-scheduled, providing no new material information regarding the company's operational performance, strategic direction, or financial health. Therefore, a seasoned investor would likely maintain their current position, as this filing does not present a catalyst for a 'buy' or 'sell' decision based on fundamental changes.

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Stock sale, Executive compensation, Bryan T. Vaughn